NR1H2 and breast carcinoma: Dual LXRα/LXRβ ligands such as 26OHC convincingly slow tumor growth through the anti-proliferative activities of LXR, yet drive LXR dependent metastasis [37] and substitute for estrogen to drive ER dependent breast cancer growth [37, 38].